首页> 外文期刊>European journal of human genetics: EJHG >Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13.
【24h】

Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13.

机译:传输比率失真和母体效应混淆了19q13上的囊性纤维化疾病严重程度调节剂的分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Two entities localised within in a 5 Mb interval on 19q13, that is the transforming growth factor beta 1 (TGFbeta1) and the cystic fibrosis modifier 1, have been reported to modulate disease severity of cystic fibrosis (CF), albeit the designation of the risk allele for TGFbeta1 differs between studies. We have analysed genotyping data at seven microsatellite loci and four single nucleotide polymorphisms targeting the 19q13 area from 37 nuclear CF families with two affected offspring exhibiting extreme clinical phenotypes for indicators of transmission-ration distortion, maternal genetic or maternal non-genetic effects. Evidence for a transmission-ratio distortion was obtained at D19S112 (P=0.0304) near the recently characterised myotonic dystrophy locus myotonic dystrophy protein kinase (DMPK). Maternal and paternal genotype distributions were significantly different at rs1982073 (Leu10Pro at TGFbeta1) whereby all CF sibs heterozygous at rs1982073 inherited the Leu10 allele from their mother (P=0.000132) in our sibling panel. To ask whether the improved survival in CF over the last decades has any influence on TGFbeta1 allele frequencies, we analysed unrelated F508del homozygotes who were stratified by birth cohort. Sensitivity with respect to the survivor bias was reflected by significantly higher incidence of mild cystic fibrosis transmembrane conductance regulator mutation genotypes in the early born patient cohort (P=0.0169), and an allelic imbalance was also observed at TGFbeta1 (P=0.0664). In conclusion, the role of TGFbeta1 as a CF modulator, suggested from studies with a case-control setting, needs to be interpreted with caution unless family-based analysis is carried out to identify parental genetic and non-genetic effects.
机译:据报道,在19q13的5 Mb间隔内定位的两个实体,即转化生长因子β1(TGFbeta1)和囊性纤维化修饰剂1,可调节疾病的囊性纤维化(CF)严重程度,尽管指定了风险TGFbeta1的等位基因在研究之间有所不同。我们已经分析了针对37个CF家族中19q13区域的七个微卫星基因座和四个单核苷酸多态性的基因分型数据,其中两个受影响的后代表现出极高的临床表型,可用于19q13区域,这些指标表现出传播率失真,母体遗传或母体非遗传效应的指标。在D19S112(P = 0.0304)附近,最近表征的强直性肌营养不良基因座,肌强直性营养不良蛋白激酶(DMPK)获得了传播比率失真的证据。在rs1982073(TGFbeta1的Leu10Pro)上,母本和父本的基因型分布存在显着差异,因此在rs1982073上,所有CF同胞杂合子均从其母亲那里继承了Leu10等位基因(P = 0.000132)。要询问过去几十年来CF存活率的提高是否对TGFbeta1等位基因频率有影响,我们分析了按出生队列分层的无关F508del纯合子。早产患者队列中轻度囊性纤维化跨膜电导调节子突变基因型的发生率显着较高,反映了对幸存者偏见的敏感性(P = 0.0169),TGFbeta1也观察到等位基因失衡(P = 0.0664)。总之,除非有基于家庭的分析来确定父母的遗传和非遗传效应,否则在进行病例对照研究时,建议谨慎地解释TGFbeta1作为CF调节剂的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号